肿瘤免疫：生物创新【研报】

pengxuleo

9 @  O2 A4 J, |0 c- n  \% i6 T7 X0 ]' B; j! b+ j9 s& V
目录
: A. r" Q2 \* x0 f/ _; z免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 42 j+ `7 ~! U( b+ ?) X) n& G
抗癌领域新突破 .................................................................................................................. 40 @6 O$ N$ t& Q
600 亿美元市场空间 ............................................................................................................ 4( w% S9 d/ P' p5 ^. t2 t3 n4 p) k
免疫检查点的突破——PD-1 ....................................................................................................... 54 I+ ?4 ^( I1 v% u+ s8 R" {
PD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5
7 z, \4 m  h( tPD-1 重磅产品频出 ............................................................................................................. 5
) d: [1 N" \9 j在研PD-1 单抗全面开花 ....................................................................................................... 69 G+ J0 s& y( V# f7 ^$ s$ n8 V
PD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 73 E- w* E! \' e, W# U% k: {
PD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
! C* F# N2 Q; E& ~% W6 a1 vPD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9
$ w+ v( A3 }% Z" KPD-1 市场前景广阔 ........................................................................................................... 104 I% R* \9 [4 a
免疫治疗热门靶点——PD-L1 ................................................................................................... 193 j7 H) x1 u' e- k$ @+ w) J: U
PD-L1 单抗免疫疗法原理 .................................................................................................... 19, P& F6 `: h% G! D# a
PD-L1 单抗在研情况 .......................................................................................................... 19& h5 p2 A+ g( L" g1 z) @: @
PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19
: o: v! H% j/ v* p2 {PD-L1 未来市场 ............................................................................................................... 20/ R& l/ s2 E% k! Q$ d; i
免疫治疗另一靶点——CTLA-4 .................................................................................................. 21& G/ O( ?* p) [- n/ q  t
CTLA-4 单抗免疫疗法原理 ................................................................................................... 219 M# S8 j0 v1 J( u! F
CTLA-4 单抗已上市产品 ..................................................................................................... 21& X5 i" X/ a* i: N- d
CTLA-4 在研产品.............................................................................................................. 22. a! w) V5 N: B' d" i* g
CTLA-4 的未来，联合用药是出路 .......................................................................................... 23
" X* T1 G' Z7 [" w9 f- H& F0 b相关公司简介 ........................................................................................................................ 24
" }* G5 X+ y/ |: c# f& N3 e; [君实生物 ........................................................................................................................ 24: `: o7 o- X% D& D
恒瑞医药（确信买入评级） .................................................................................................. 258 g/ @( @5 [6 N6 K- q! p: Q
百时美施贵宝（BMS） ....................................................................................................... 26
. U8 e" M# f: x默克（Merck） ................................................................................................................ 27
# u6 K$ N; e- i9 }+ N
% _# T8 C3 ~6 M& }; M1 E" T
7 E* N- `+ r6 s( j! ?- m& h[hide][/hide]

ljf452719

好好学习

wzs1985

这两年最火的东西，谢谢了啊

11yzhangy8

好东西。看看

h3636

看看

zhengjianwei521

sky-sky

谢谢分享' Q* Z) p, F5 Y: t+ B. c% o" j

小云龙

学习

hameln

看看

xy7500

了解
; {" K0 y! @8 M1 a8 Q一下